Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tranexamic acid
Drug ID BADD_D02261
Description Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.[L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]
Indications and Usage Dunn CJ, Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32.
Marketing Status Prescription; Discontinued
ATC Code B02AA02
DrugBank ID DB00302
KEGG ID D01136
MeSH ID D014148
PubChem ID 5526
TTD Drug ID D05HXX
NDC Product Code 12079-2001; 71052-166; 42571-314; 51754-0108; 67457-197; 71335-1957; 69918-301; 60505-6169; 70860-400; 0591-3720; 63629-8838; 67850-041; 50090-5072; 0013-1114; 51552-0513; 38779-3211; 42571-189; 49452-7877; 67850-042; 81999-0001; 43066-008; 72485-107; 68382-891; 39822-1000; 55150-188; 72611-760; 50090-4530; 49452-7876; 12848-1004; 71335-1981; 70121-1398; 51662-1532; 65388-0156; 61990-0611; 63323-563; 65145-106; 23155-166; 38779-2794; 81284-611; 70771-1085; 73309-178; 57218-951; 63629-8599; 51927-0022; 63759-0038; 62991-3131; 69918-300; 17478-017; 0517-0960; 81284-612; 17478-018; 62559-265; 68083-160; 55566-2110; 23155-524
Synonyms Tranexamic Acid | AMCHA | trans-4-(Aminomethyl)cyclohexanecarboxylic Acid | t-AMCHA | AMCA | Anvitoff | Cyklokapron | Ugurol | KABI 2161 | Spotof | Transamin | Amchafibrin | Exacyl
Chemical Information
Molecular Formula C8H15NO2
CAS Registry Number 701-54-2
SMILES C1CC(CCC1CN)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tremor17.01.06.002--
Type I hypersensitivity10.01.03.0060.014288%Not Available
Unresponsive to stimuli17.02.05.0310.021433%Not Available
Urticaria23.04.02.001; 10.01.06.0010.028577%
Uterine leiomyoma21.07.02.004; 16.04.02.0010.014288%Not Available
Vasodilatation24.03.02.003; 23.06.05.0060.014288%Not Available
Vena cava thrombosis24.01.10.0010.005591%Not Available
Venous thrombosis24.01.01.0080.035721%Not Available
Ventricular arrhythmia02.03.04.006--
Ventricular fibrillation02.03.04.0080.007455%
Ventricular tachycardia02.03.04.0100.014288%
Vertigo17.02.12.002; 04.04.01.0030.014288%
Viral upper respiratory tract infection11.05.04.007; 22.07.02.0040.021433%Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.0080.014288%Not Available
Vomiting07.01.07.003--
Wheezing22.03.01.0090.021433%
Factor VIII inhibition01.01.02.0120.028577%Not Available
Intracardiac thrombus24.01.05.003; 02.01.01.0070.003727%Not Available
Seasonal allergy10.01.04.001; 06.04.01.013; 22.04.04.008--Not Available
Allergic sinusitis22.04.06.003; 10.01.03.021--Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.014288%
Deep vein thrombosis24.01.02.0030.114308%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Haemodynamic instability24.03.02.0060.007455%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Myoclonic epilepsy17.12.03.0070.021433%Not Available
Haemorrhage24.07.01.0020.107164%Not Available
Venous occlusion24.04.02.009--Not Available
Angiopathy24.03.02.007--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages